Canagliflozin 300mg Tablets

Canagliflozin-Tablets300mg
  • Dosage: Canagliflozin 300mg
  • Packaging: 10tablets/blister*1/box
  • Shelf Life: 36months 

Click to add this item to cart.

Product Description

Product NameCanagliflozin Tablets (Canagliflozin 300mg Oral Tablets)
SpecificationEach tablet contains: Canagliflozin 300mg
Dosage FormOral Film-Coated Tablet (for oral administration)
Active IngredientCanagliflozin
Pharmacological ClassSodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Antidiabetic Agent)
Route of AdministrationOral administration (swallowed whole with water; take before the first meal of the day). Take at approximately the same time each morning.
PackagingBlister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Shelf Life24 months (unopened)

Product Overview

Canagliflozin Tablets is an oral preparation containing Canagliflozin 300mg per film-coated tablet. Canagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. SGLT2 inhibitors work by a mechanism that is independent of insulin secretion, which differentiates them from other classes of antidiabetic medications.

Canagliflozin 300mg Tablets: What the Published Guidance Says

Human and analogue insulins alongside the oral hypoglycaemics and cardiorenal-metabolic agents added to the WHO Model List in its September 2025 revision.

This page collects the supply-relevant facts for Canagliflozin 300mg Tablets — specification, testing, packaging and the registration paperwork that travels with the batch.

  • SGLT2 inhibitors are on the Model List Section 18.5.2 lists empagliflozin as a 10 mg and 25 mg tablet for type 2 diabetes mellitus, with canagliflozin and dapagliflozin named as therapeutic equivalents. WHO eEML — Medicines for diabetes
  • The Model List details the insulin presentations and strengths Section 18.5.1 of the 24th WHO Model List (2025) lists human short-acting insulin as an injection solution of 40 IU/mL or 100 IU/mL in 10 mL vials and 100 IU/mL in 3 mL cartridges or pre-filled pens. Human intermediate-acting insulin is listed as an injection suspension in the same strengths, as compound insulin zinc suspension or isophane insulin. Long-acting and rapid-acting analogues are listed with glargine, degludec and detemir named among the therapeutic alternatives — a footnote notes that quality-assured biosimilars are included. WHO eEML — Medicines for diabetes
  • The scale of the access problem WHO reports that more than 800 million people were living with diabetes in 2022, with half going untreated, and that more than one billion people worldwide are affected by obesity with rates rising fastest in low- and middle-income countries. WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)

We quote these sources rather than paraphrase them loosely, because the detail matters commercially for Canagliflozin 300mg Tablets. Where your national list differs from the WHO listing, the national list governs what may be supplied and promoted locally.

Canagliflozin 300mg Tablets: Specification, Pack & Documentation Summary

Product NameCanagliflozin Tablets (Canagliflozin 300mg Oral Tablets)
SpecificationEach tablet contains: Canagliflozin 300mg
Dosage FormOral Film-Coated Tablet (for oral administration)
Active IngredientCanagliflozin
Pharmacological ClassSodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Antidiabetic Agent)
Route of AdministrationOral administration (swallowed whole with water; take before the first meal of the day). Take at approximately the same time each morning.
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Therapeutic groupDiabetes & Insulin — Diabetes & Insulin
ManufacturerSinophare Bio-technology Co., Ltd. (GMP, China)
Documentation suppliedCOA, HPLC/GC data, stability data, dossier package

The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Dapagliflozin 10mg Tablets, Empagliflozin 25mg Tablets, Ertugliflozin 15mg Tablets, Finerenone 20mg Tablets, Repaglinide Tablets 2mg, Sotagliflozin 400mg Tablets, Mixed Protamine Human Insulin 30R, Insulin Glargine Injection 100IU/mL 3ml Cartridge.

How Canagliflozin 300mg Tablets Is Tested and Released

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Every batch of Canagliflozin 300mg Tablets is tested to the monograph stated on the purchase order. Where a monograph is silent on the presentation, we agree a written specification with you in advance and reference it on the certificate of analysis.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Release testing on this presentation is built around:

  • Testing for related substances and impurities
  • Testing for dissolution or release profile (solid oral forms)
  • Testing for uniformity of dosage units
  • Testing for water content and pH where applicable
  • Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
  • Testing for microbial limits and preservative efficacy (multi-dose presentations)

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

How Canagliflozin 300mg Tablets Is Packed, Labelled and Shipped

  • Pack size: Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Non-standard pack sizes can be quoted against your artwork.
  • Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
  • Shelf life: 24 months (unopened). Stability data for the marketed pack is included in the dossier.
  • Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
  • Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Regulatory Support for Canagliflozin 300mg Tablets

Documents for Canagliflozin 300mg Tablets are issued by Sinophare Bio-technology Co., Ltd. — DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. Keeping one legal manufacturer across the COA, the GMP certificate and the registration file avoids assessment queries later.

  • Method validation, stability protocol and the shelf-life justification for the marketed pack.
  • Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
  • Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
  • Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
  • Batch manufacturing and packaging records released for inspection on request during supplier audits.

The context for Canagliflozin 300mg Tablets is its place among medicines for diabetes listed in the WHO Model List. Listing status informs how programmes specify a product; it is not a substitute for the import licence or marketing authorisation of the destination country.

Questions We Are Asked About Canagliflozin 300mg Tablets

What pack size is available for Canagliflozin 300mg Tablets?

This presentation is normally supplied as Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Where your market requires a different count, bottle or carton, we quote to your artwork and extend the stability file to the new pack.

What documentation comes with a shipment of Canagliflozin 300mg Tablets?

Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 24 months.

Does the batch documentation for Canagliflozin 300mg Tablets support a registration filing?

Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 24 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.

How is insulin shipped?

Under temperature-controlled conditions with shipment temperature records. Confirm the exact cold-chain specification required for your market before ordering.

Can you support an insulin registration dossier?

Yes — we provide DMF and dossier packages with registration support documents. DML Number Jin20160068 covers medicines production.

Companion Products — Diabetes & Insulin

Browse the full Diabetes & Insulin range; all Tablets; the complete product catalogue.

Request a Quotation for Canagliflozin 300mg Tablets

For tenders and programme supply, send the line item, pack size, quantity and destination for Canagliflozin 300mg Tablets 300mg. We return a quotation with lead time, documentation list and sample availability in one response.

Request a quotation

Sources & Regulatory Notes

Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.

<< return to products